The National Perinatal Association’s 2015 guidelines for preventative RSV (respiratory syncytial virus) treatment send a clear message about protecting pre-term infants: the FDA indication stands. The guidance directly contrasts guidelines issued by the American Academy of Pediatrics earlier this year. AAP guidelines restricted access to only infants born before 29 weeks gestation, provoking outcry from health care providers about the risks that fragile infants will bear this RSV season.